Gilead Sciences Inc. (NASDAQ:GILD) ~ The Most Important New Drug Of 2013
December 26, 2013 at 12:04 PM EST
[at Forbes] – Gilead Sciences’ Sovaldi, for hepatitis C, was the most important new medicine approved this year. It heralds the hope that a viral disease that afflicts more than 3 million Americans, . . . → Read More: Gilead Sciences Inc. (NASDAQ:GILD) ~ The Most Important New Drug Of 2013 Similar posts: Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol drug for fat disorder may work, but risky -FDA staff Gilead Sciences Inc. (NASDAQ:GILD) – Gilead’s Hepatitis C Pill Works Better, FDA Report Says Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review